Download PDF
Zeitschrift für Orthomolekulare Medizin 2023; 21(01): 8-12
DOI: 10.1055/a-2009-3541
Wissen

Long-COVID und Post-COVID-Syndrom

Burkhard Schütz
,
Meike Crecelius
› Further Information
    Permissions and Reprints

Zusammenfassung

Unter dem Post-COVID-Syndrom (PCS) versteht man eine länger als 12 Wochen anhaltende Symptomatik mit Fatigue, Kurzatmigkeit, eingeschränkter Leistungsfähigkeit u. a., die bei rund 15% der Patienten nach einer akuten Infektion mit SARS-CoV-2 auftritt. Als Ursache werden Veränderungen im Mikrobiom und Störungen des Tryptophanstoffwechsels diskutiert, welche zu einer vermehrten Umwandlung von Tryptophan in prooxidativ und proinflammatorisch wirkende Abbauprodukte führen. Nach aktuellen Studien können infolge der Infektion latente Viren wie Epstein-Barr-, Cytomegalie- und Varizella-Zoster-Virus reaktiviert werden und PCS-typische Symptome auslösen. Eine überschießende Entzündungsreaktion bei COVID-19 führt zur Bildung von Autoantikörpern, die durch Einschränkung der Immunantwort die Virusbekämpfung erschweren. Therapeutisch kann eine Supplementierung von Mikronährstoffen wie Vitamin C, D, E, B6, B12, ω-3-Fettsäuren und Coenzym Q10 sinnvoll sein.

Schlüsselwörter

Long-COVID - Post-COVID-Syndrom - Diagnostik - Tryptophan-Stoffwechsel - Mikrobiom - Epstein-Barr-Virus - Herpesviren - Autoantikörper - Therapie - Mikronährstoffe


Publication History

Article published online:
24 March 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e. V. S1-Leitlinie Long-/Post-COVID; Registernummer 020–027 https://register.awmf.org/de/leitlinien/detail/020-027 (Stand: 03.01.2023)
  • 2 Garg P. et al. The „post-COVID“ syndrome: How deep ist the damage?. Journal of Medical Virology 2021; 93: 673-674
    CrossrefPubMedGoogle Scholar
  • 3 Goërtz YMJ. et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?. ERJ Open Research 2020; 6: 00542-02020
    PubMedGoogle Scholar
  • 4 Pal R. COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications. Endocrine 2020; 68: 251-252
    CrossrefPubMedGoogle Scholar
  • 5 Russell A. et al. Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. Psychoneuroendocrinology 2019; 100: 276-285
    CrossrefPubMedGoogle Scholar
  • 6 Naviaux RK. et al. Metabolic features of chronoc fatigue syndrome. Proc Natl Acad Sci U S A 2016; 113: E5472-E5480
    PubMedGoogle Scholar
  • 7 Wood E. et al. Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitit/chronic fatigue syndrome: A possible approach to SARS-CoV-2 ‚long-haulers‘?. Chronic Dis Transl Med 2021; 7: 14-26
    PubMedGoogle Scholar
  • 8 Thomas T. et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight 2020; 5: e140327
    CrossrefPubMedGoogle Scholar
  • 9 Barberis E. et al. Large-Scale Plasma Analysis Revealed New Mechanisms and Molecules Associated with the Host response to SARS-CoV-2. International Journal of Molecular Sciences 2020; 21: 8623
    CrossrefPubMedGoogle Scholar
  • 10 Lionetto L. et al. Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study. BBA-Molecular Basis of Disease 2020; 1867: 166042
    CrossrefPubMedGoogle Scholar
  • 11 Cervenka I. et al. Kynurenines: Tryptophan’s metabolites in exercise, inflammation and mental health. Science 2017; 357: eaaf9794
    CrossrefPubMedGoogle Scholar
  • 12 Yamashita M. et al. Potential Role of Neuroactive Tryptophan Metabolites in Central Fatigue: Establishment of the Fatigue Circuit. International Journal of Tryptophan Research 2020; 13: 1178646920936279
    CrossrefPubMedGoogle Scholar
  • 13 Németh H. et al. Role of kynurenines in the central and peripheral nervous systems. Current Neurovascular Research 2005; 2: 249-260
    CrossrefPubMedGoogle Scholar
  • 14 Yamamoto T. et al. Essential role of excessive tryptophan and its neurometabolites in fatigue. Canadian Journal of Neurological Sciences 2012; 39: 40-47
    CrossrefPubMedGoogle Scholar
  • 15 Zuo T. et al. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge. Gastroenterology 2020; 159: 1302-1310
    CrossrefPubMedGoogle Scholar
  • 16 Zuo T. et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology 2020; 159: 944-955
    CrossrefPubMedGoogle Scholar
  • 17 Kinashi Y, Hase K. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity. Front Immunology 2021; 12: 673708
    CrossrefPubMedGoogle Scholar
  • 18 Choi SC. et al. Gut microbiota dysbiosis and altered tryptophan catabolism contribute to autoimmunity in lupus-susceptible mice. Sci Transl Med 2020; 8: 551
    Google Scholar
  • 19 Solomay TV. et al. Reactivation of Epstein-Barr virus (Herpesviridae: Lymphocryptovirus, HHV-4) infection during COVID-19: epidemiological features. Problems of Virology 2021; 66: 152-161
    CrossrefPubMedGoogle Scholar
  • 20 Smatti MK. et al. Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Frontiers in Oncology 2018; 8: 211
    CrossrefPubMedGoogle Scholar
  • 21 Xie Y. et al. Clinical characteristics and outcomes of critically ill patients with acute COVID-19 with Epstein-Barr virus reactivation. BMC Infectious Disaeses 2021; 21: 1-8
    Google Scholar
  • 22 Simonnet A. et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infectious Diseases Now 2021; 51: 296-299
    CrossrefPubMedGoogle Scholar
  • 23 Rojas M. et al. Autoimmunity is a hallmark of post-COVID syndrome. Journal of translational medicine 2022; 20: 1-5
    CrossrefPubMedGoogle Scholar
  • 24 Chang S. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nature communications 2021; 12: 1-15
    CrossrefPubMedGoogle Scholar
  • 25 Gao ZW. et al. Autoantibodies in COVID-19: frequency and function. Autoimmunity Reviewes 2021; 20: 102754
    CrossrefPubMedGoogle Scholar
  • 26 Wang EY. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 2021; 595: 283-288
    CrossrefPubMedGoogle Scholar
  • 27 Doaei S. et al. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. Journal of translational medicine 2021; 19: 1-9
    CrossrefPubMedGoogle Scholar
  • 28 Vollbracht C. et al. Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue. Nutrients 2021; 13: 1154
    CrossrefPubMedGoogle Scholar
  • 29 Banerjee RV. et al. Cobalamin-dependent methionine synthase. FASEB Journal 1990; 4: 1450-1459
    CrossrefPubMedGoogle Scholar
  • 30 Kryukov EV. et al. Plasma S-Adenosylmethionine Is Associated with Lung Injury in COVID-19. Disease Markers 2021; 7686374
    PubMedGoogle Scholar
  • 31 Gvozdjakova A. et al. Is mitochondrial bioenergetics and coenzyme Q10 the target of a virus causing COVID-19?. Bratislavske lekarke listy 2020; 121: 775-778
    Google Scholar
  • 32 Akhtar S. et al. Nutritional perspectives for the prevention and mitigation of COVID-19. Nutrition reviews 2021; 79: 289-300
    CrossrefPubMedGoogle Scholar
  • 33 Bastard P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 2021; 6 (62): eabl4340
    CrossrefPubMedGoogle Scholar